- CytoDyn
will present on October 1 at 9 a.m. EST (6 a.m. PST) at The Microcap
Conference at the Essex House in New York City, with live webcast
available
- CYDY
is a biotechnology company developing humanized monoclonal antibodies for
the treatment of multiple therapeutic indications, such as HIV, tumor
metastasis and graft-vs-host disease
CytoDyn Inc. (OTCQB: CYDY) management is set to present at
The Microcap Conference on October 1 at the Essex House in New York at 9 a.m.
EST (http://ibn.fm/CEGgV).
The MicroCap presentation will be available on live webcast, and a replay will
be hosted on the investor’s section of the company’s website at http://ir.CytoDyn.com.
CYDY is in advanced clinical development with PRO 140, a
leading monoclonal antibody for the treatment and prevention of HIV, which
offers potential both in combination with other HIV treatments and as
single-agent therapy. PRO 140 is a humanized IgG4 monoclonal antibody that
blocks CCR5, a cellular receptor that plays multiple roles with implications in
HIV infection, tumor metastasis and immune signaling.
In the setting of HIV/AIDS, PRO 140 belongs to a new class
of therapeutics called viral-entry inhibitors; it masks CCR5, thus protecting
healthy T cells from viral infection by blocking the predominant HIV (R5)
subtype from entering those cells. At the same time, PRO 140 does not appear to
interfere with the normal function of CCR5 in mediating immune responses. PRO
140 has been the subject of seven clinical trials, each demonstrating efficacy
by significantly reducing or controlling HIV viral load in human test subjects.
PRO 140 has been designated a “fast track” product by the FDA. The PRO 140
antibody appears to be a powerful antiviral agent leading to potentially fewer
side effects and less frequent dosing requirements compared with daily drug
therapies currently in use.
In the setting of cancer, research has shown that CCR5 plays
a central role in tumor invasion and metastasis and that expression of CCR5 is
an indicator of disease status in several cancers. Moreover, researchers have
shown that drugs that block CCR5 can block tumor metastases in laboratory and
animal models of aggressive breast and prostate cancer. In human pilot trials,
CCR5 inhibition has been shown to remarkably limit colon cancer metastasis.
CytoDyn is conducting additional research with PRO 140 in the cancer setting
and plans to initiate Phase 2 human clinical trials when appropriate.
The CCR5 receptor also plays a central role in modulating
immune cell trafficking to sites of inflammation, and it is crucial for the
development of acute graft-versus-host disease (GvHD) and other inflammatory
conditions. Clinical studies by others have shown that blocking CCR5 using a
chemical inhibitor can reduce the clinical impact of acute GvHD without
significantly affecting the engraftment of transplanted bone marrow stem cells.
CytoDyn is currently conducting a Phase 2 clinical study with PRO 140 to
further support the concept that the CCR5 receptor on engrafted cells is
critical for the development of acute GvHD and that blocking this receptor from
recognizing certain immune signaling molecules is a viable approach to
mitigating acute GvHD. The FDA has granted orphan drug designation to PRO 140
for the prevention of graft-versus-host disease (GvHD).
For more information, visit the company’s website at www.CytoDyn.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment